香港交易及結算所有限公司及香港聯合交易所有限公司對本公布的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公布全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 朗廷酒店投資 （根據香港法例按日期為二零一三年五月八日之信託契約組成， 其託管人為朗廷酒店管理人有限公司） 與 朗廷酒店投資有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1270） 2025 年度全年業績公布 朗廷酒店管理人有限公司（作為朗廷酒店投資（「本信託」）的託管人－經理（「託管人 －經理」））及朗廷酒店投資有限公司（「本公司」）之董事會（「董事會」）欣然宣布， 本信託及本公司連同本公司之附屬公司（「信託集團」）截至 2025 年 12 月 31 日止年度 之綜合業績如下： 財務摘要 | （除另有指明外，以百萬港元為單位） | 2025 年 | 2024 | 年 | 變幅 | | --- | --- | --- | --- | --- | | 酒店組合收入 | 1,575.3 | | 1,587.7 | -0.8% | | 酒店組合的合計總經營毛利（扣除全球市 | | | | | | 場 ...

HPC HOLDINGS LIMITED 股份代號 1742 (於開曼群島註冊成立之有限公司) 2024/25 年 報 公司資料 2 目錄 主席報告 3 履歷詳情 4 管理層討論及分析 6 企業管治報告 12 董事會報告 27 環境、社會及管治報告 36 獨立核數師報告 71 綜合全面收益表 76 綜合資產負債表 77 綜合權益變動表 79 綜合現金流量表 80 綜合財務報表附註 82 五年期間之財務概要 130 公司資料 註冊辦事處 Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands 總部及新加坡主要營業地點 7 Kung Chong Road HPC BUILDING Level 6 Singapore 159144 香港主要營業地點 香港 北角電氣道148號31樓 董事名單與其角色和職能 執行董事 王應德先生 （主席兼行政總裁） 施建華先生 （首席運營官） 獨立非執行董事 梁偉業先生 陳力萍女士 趙文耀先生（於二零二五年十二月三十一日獲委任） 鄞雲亮先生（於二零二五年十二月三十一日辭任） 審核委 ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「香港聯交所」）對本公告的內 容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不會就本公告全部或 任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 NetEase, Inc. （於開曼群島註冊成立的有限責任公司） （股份代號：9999） 2025 年 12 月 31 日止第四季度及財政年度 未經審計的財務業績公告及第四季度股息公告 網易股份有限公司（「公司」）在此公佈 2025 年第四季度的季度股息及第四季度及財政年度 業績公告， 其中包含截至 2025 年 12 月 31 日的三個月及財政年度未經審計的財務業績。本業 績公告可於香港聯交 所網站 www.hkexnews.hk 及公司網站 http://ir.netease.com 閱覽。 承董事會命 NetEase, Inc. 丁磊 董事 中國杭州，2026 年 2 月 11 日 於本公告日期，本公司董事會包括董事丁磊先生；以及獨立董事唐徽女士、鄭玉芬女士、唐子期先生、 梁民傑先生及陳覺忠先生。 淨收入為人民幣 275 億元（39 億美元），同比增加 3.0%。 遊戲及相關增 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 TAI PING CARPETS INTERNATIONAL LIMITED 太平地氈國際有限公司* （於百慕達註冊成立之有限公司） （股份代號：146） 管理層討論與分析 業務回顧 本集團錄得綜合營業額約為港幣309,000,000元，較二零二四年同期錄得的約為港幣 308,000,000元有稍微增長。毛利率持穩在62% ，反映穩定的產品組合及嚴謹的定價機 制。 分銷及行政費用總額按年增加5% ，主要原因是對銷售及分銷活動進行針對性投資，包括 參與新的推廣活動，以及創建新的內容及數碼營銷渠道，藉此促進長遠增長。儘管本集 團聚焦於商業活動，但對於行政支出仍維持審慎的策略，以精準及有效地控制各項支援 職能的成本。 * 中文名稱僅供識別 截至二零二五年十二月三十一日止六個月 中期業績 太平地氈國際有限公司* （「本公司」）董事會（「董事會」）特此提呈本公司及其附屬公司（「本 集團」）截至二零二五年十二月三十一 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 NETEASE CLOUD MUSIC INC. 網易雲音樂股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9899） 截至2025年12月31日止年度的 年度業績公告 董事會欣然宣佈本公司及其子公司（統稱「本集團」）截至2025年12月31日止年度 的未經審計合併業績。該等未經審計合併年度業績已由董事會的審計委員會連 同我們的管理層審閱。 一般附註 於本公告：(i)「我們」及「我們的」指本公司及倘文義另有所指，則指本集團； (ii)數字可能會約整至小數點後一位或兩位；及(iii)除另有所指外，所用匯率為 人民幣1元兌1.1071港元及0.1423美元。 2 管理層討論與分析 截至12月31日止年度 | | 2025年 | 2024年 | 變動(%) | | --- | --- | --- | --- | | | | （人民幣千元，百分比除外） | | | 收入 | 7,759,450 | ...

Financial Performance - For the fiscal year 2025, the company recorded revenue of approximately 260.0 million MYR, a decrease of about 29.2 million MYR or 10.0% compared to 289.2 million MYR in fiscal year 2024[9]. - The company reported a loss attributable to owners of approximately 3.8 million MYR for fiscal year 2025, an increase of about 2.2 million MYR from a loss of 1.6 million MYR in fiscal year 2024[9]. - The gross profit margin improved from approximately 1.4% in fiscal year 2024 to about 5.1% in fiscal year 2025[9]. - The gross profit increased from approximately RM 4.0 million in fiscal year 2024 to approximately RM 13.1 million in fiscal year 2025, with the gross profit margin rising from 1.4% to 5.1%[24]. - The group’s revenue for the fiscal year 2025 was approximately 259.9 million MYR, a decrease of 10.1% from 289.2 million MYR in 2024[180]. - The cost of services for the fiscal year 2025 was approximately 246.8 million MYR, down from 285.1 million MYR in 2024[180]. - The group reported a gross profit of approximately 13.1 million MYR for fiscal year 2025, compared to 4.0 million MYR in 2024, marking a significant improvement[180]. - The pre-tax profit for the fiscal year 2025 was approximately 6.8 million MYR, a recovery from a loss of 0.8 million MYR in 2024[180]. - The total assets of the group as of October 31, 2025, were approximately 240.9 million MYR, a decrease from 292.5 million MYR in 2024[180]. - The total liabilities of the group were approximately 116.3 million MYR, down from 141.1 million MYR in 2024[180]. Project and Contract Management - As of October 31, 2025, the company had five ongoing construction projects with a total contract value of approximately 587.9 million MYR[19]. - The company completed one factory project in fiscal year 2025 with a total contract value of approximately 83.1 million MYR[16]. - The company submitted four bids for factory projects, one for commercial projects, one for institutional projects, and two for infrastructure projects in fiscal year 2025[20]. - The company won contracts for one factory and two infrastructure projects, with total contract values of approximately 186.2 million MYR and 35.0 million MYR respectively[20]. - As of October 31, 2025, the company's uncompleted engineering order book amounts to approximately RM 260.6 million, down from RM 278.9 million as of October 31, 2024[23]. Operating Environment and Strategy - The company anticipates facing a challenging operating environment in the next fiscal year due to global uncertainties and increased competition[11]. - The company plans to adopt a cautious strategy, focusing on selective project participation and strict cost management to ensure operational sustainability and resilience in the competitive Malaysian construction market[32]. Shareholder and Dividend Information - A special dividend was declared on September 24, 2025, to reward shareholders for their support[10]. - The proposed final cash dividend for the fiscal year 2025 is 0.027 HKD per share, subject to approval at the annual general meeting[176]. - The company has adopted a dividend policy effective from November 20, 2020, aiming to balance shareholder interests with prudent capital management[163]. - The board will consider various factors, including actual and expected financial performance, when deciding on dividend payments[163]. - There is no predetermined dividend payout ratio, and the board retains discretion over the declaration and amount of dividends[164]. Governance and Leadership - The company has a strong leadership team with extensive experience in the construction industry, ensuring effective management and operational oversight[67]. - The board includes independent directors who provide oversight and governance, enhancing the company's compliance and strategic direction[68]. - The roles of the Chairman and CEO have been clearly separated, with Low Seah Sun serving as Chairman and Low Wui Linn as CEO for the fiscal year 2025[77]. - The company has adopted the corporate governance code as per the Stock Exchange Listing Rules, ensuring compliance with all governance code provisions for the fiscal year 2025[76]. - The company has established a remuneration committee and an audit committee, enhancing oversight and governance practices[76]. Risk Management - The group has established a risk register to document identified risks, their ratings, mitigation plans, and responsible parties[131]. - The internal control system is reviewed annually to ensure its effectiveness, with an independent consultant conducting evaluations[132]. - The board concluded that the risk management and internal control systems are effective and adequate for the fiscal year 2025[132]. - Compliance risk management is crucial for adhering to legal regulations and industry standards[133]. - Financial risk management procedures enable the group to effectively manage financial resources and obligations[134]. - Business risks are assessed based on severity and likelihood to capture opportunities and implement mitigation measures[136]. Shareholder Communication - The company has established a shareholder communication policy to ensure timely access to comprehensive information for shareholders[149]. - The board will regularly review the effectiveness of the shareholder communication policy to ensure it meets shareholder needs[154]. - The company encourages shareholder participation in annual general meetings and allows for proxy voting if shareholders cannot attend[152]. Audit and Compliance - The Audit Committee held 3 meetings in the fiscal year 2025, reviewing the financial statements and ensuring compliance with applicable accounting standards[119]. - The external auditor, ShineWing (HK) CPA Limited, was recommended for reappointment at the 2025 Annual General Meeting, having demonstrated independence and objectivity[120]. - The total fees paid to the external auditor for audit services in 2025 amounted to 585,000 MYR, slightly down from 586,000 MYR in 2024[125]. - The Audit Committee assessed the effectiveness of the internal audit function conducted by independent professional advisors[122]. - The company confirmed that there are no significant uncertainties affecting its ability to continue as a going concern, and financial statements were prepared on a going concern basis[128].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本文檔全部或任何部份內容而産生或因倚賴該等內容而引致 的任何損失承擔任何責任。 SEMICONDUCTOR MANUFACTURING INTERNATIONAL CORPORATION 中芯國際集成電路製造有限公司 * (於開曼群島注冊成立之有限公司) (股份代號：00981) 中芯國際截至 2025年 12月 31日止三個月未經審核業績公佈 除非以下額外說明，本合併財務信息係依國際財務報告準則編製且表達。 以下爲本公司及其子公司(「本集團」)於 2026 年 2 月 10 日就截至 2025 年 12 月 31 日止三個月的未經 審核業績公佈全文。 除非特別指明，所有貨幣以美元列賬。 中國上海─ 2026 年 2 月 10 日─ 國際主要半導體代工製造商中芯國際集成電路製造有限公司(香港聯交所 股份代號：00981；上交所科創板證券代碼：688981)(「中芯國際」、「本公司」或「我們」)於今日公佈 截至 2025 年 12 月 31 日止三個月的綜合經營業績。 * 僅供識別 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲 明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 PCCW Limited ( 於香港註冊成立的有限公司 ) (股份代號: 00008) 截至 2025 年 12 月 31 日止年度業績公告 電訊盈科有限公司（「電訊盈科」或「本公司」）董事（「董事」）謹此宣佈本公司及其附屬公司 （統稱「本集團」）截至 2025 年 12 月 31 日止年度的經審核綜合業績。 1 • Viu付費用戶淨增加130萬名，總數達1,680萬名5，推動訂購收益增長百分之十三 • ViuTV的數碼會員數目達340萬名，預期在精彩的團體演唱會和更龐大的藝人陣容推動下， 於2026年恢復增長 • 收益增加百分之七至港幣402.52億元 • 香港電訊收益增長百分之五至港幣365.53億元 • OTT業務收益上升百分之五至港幣25.79億元 • 免費電視及相關業務收益為港幣10.34億元 • EBITDA增加百分之三至港幣132.90億元 • 香港電訊EBITDA上升百分之四至港幣142. ...

Genetic Testing and Diagnostic Solutions - As of June 30, 2025, the company has conducted over 24 million genetic tests, making it the largest consumer genetic testing platform in China by cumulative testing volume [11]. - The company has developed 114 commercialized testing solutions for consumer genetic testing and cancer screening, with 94 of these being independently developed [12]. - The company offers a range of services, including brain health assessment, nutritional absorption capability assessment, and comprehensive cancer risk assessment [12]. - The company is developing eight in vitro diagnostic (IVD) pipeline products, including three consumer-grade genetic testing kits for assessing risks of various diseases, with regulatory approval expected by 2025 [13]. - The ApoE genetic testing kit, which assesses Alzheimer's disease risk, utilizes a blood nucleic acid non-extraction technology, reducing testing costs and time [16]. - The folate metabolism assessment kit provides guidance for pregnant women to prevent neonatal defects and assess risks of cardiovascular diseases, with regulatory approval expected by 2025 [17]. - The Alzheimer's disease screening kit is based on plasma miRNA biomarkers, with clinical validation involving at least 1,500 samples and collaboration with multiple hospitals [18]. - The colorectal cancer screening kit is based on plasma DNA methylation biomarkers, with preliminary screening completed and collaboration with three hospitals for clinical validation [20]. - The gastric cancer screening kit also utilizes plasma DNA methylation biomarkers, with similar development and validation processes as the colorectal cancer kit [24]. - The BRCA1/BRCA2 genetic mutation testing kit has completed formulation development and established a database of tens of thousands of mutation sites [29]. - The company anticipates developing qPCR and NGS testing kits for various diseases, with expected sensitivity and specificity greater than 90% [22]. - The qPCR kits for colorectal and gastric cancer will include three biomarkers and are expected to enter the IVD registration phase by 2027 [23][27]. - The company is focusing on diseases with high prevalence and lack of effective screening methods, aiming to expand its product offerings in the diagnostic market [13]. Financial Performance - The company achieved a revenue of RMB 81.3 million, representing a year-on-year decline of 24.2% [44]. - The net profit for the period was RMB 27.3 million, down 26.3% year-on-year, primarily due to adjustments in sales strategy and fixed costs [44]. - For the six months ended June 30, 2025, the company reported revenue of RMB 81.3 million, a decrease of 24.2% compared to RMB 107.3 million for the same period in 2024 [46]. - The gross profit for the same period was RMB 60.1 million, down 13.6% year-over-year, with a gross margin of 74.0%, an increase of 9.1 percentage points from the previous year [48]. - Net profit for the six months ended June 30, 2025, was RMB 27.3 million, representing a decline of 26.3% compared to RMB 37.0 million in 2024 [56]. - The revenue from consumer-grade genetic testing services was RMB 75.9 million, while cancer screening services generated RMB 5.3 million, with the latter showing an impressive growth of 85.7% year-over-year [46]. - Total revenue for the six months ended June 30, 2025, was RMB 812.81 million, down from RMB 1,072.91 million in the same period of 2024 [59]. - The cost of sales decreased by 43.9% from RMB 376.73 million in 2024 to RMB 211.41 million in 2025, primarily due to lower revenue [62]. - Gross profit for the six months ended June 30, 2025, was RMB 601.40 million, with a gross margin of 74.0%, compared to RMB 696.18 million and 64.9% in 2024 [63]. - Other income increased by 22.5% from RMB 34 million in 2024 to RMB 42 million in 2025, mainly due to higher interest income [66]. - Selling and distribution expenses decreased by 23.4% from RMB 136 million in 2024 to RMB 104 million in 2025, reflecting reduced sales costs [67]. Research and Development - The company has a strong internal R&D team, with approximately 65% of members holding master's degrees or higher from prestigious institutions [33]. - The company plans to enhance its R&D capabilities by recruiting more professionals and collaborating with renowned academic and medical institutions [51]. - The company aims to develop low-cost, home-testing screening products to diversify its product portfolio and strengthen its market leadership [51]. - The cancer screening market is expected to grow, with the company focusing on increasing automation in production to reduce costs and improve product sensitivity and specificity [50]. - The company is in the early development stages of diagnostic kits for lung nodules and cervical cancer screening [40]. - The company has developed a non-invasive oral swab sampler to enhance accessibility and affordability of genetic testing for various demographics [41]. - The company collaborates with leading medical experts to accelerate clinical trials and enhance product reliability [34]. Corporate Governance and Compliance - The company has maintained compliance with corporate governance codes and standards throughout the reporting period [138][139]. - The company has not adopted any new or revised Hong Kong Financial Reporting Standards that are not yet effective, indicating a stable accounting policy environment [156]. - The company has assessed the impact of the revised Hong Kong Financial Reporting Standards and found no significant effect on its financial position or performance [154]. - The company operates as a single reportable operating segment, focusing on overall business performance rather than service-based divisions [159]. - The company has maintained the classification of its liabilities as current or non-current following the adoption of the revised standards, with no changes expected [154]. - The company is preparing to apply the new and revised Hong Kong Financial Reporting Standards upon their effective date, ensuring compliance and accuracy in financial reporting [156]. Shareholder Information and Equity - As of June 30, 2025, Dr. Yu Rong holds 18,795,135 shares (8.38%) and has an additional 22,000,000 shares (9.81%) through controlled entities [120]. - Ms. Guo Meiling owns 22,273,970 shares (9.93%) through controlled entities and 4,545,000 shares (2.03%) as beneficial ownership [120]. - Ms. Lin Lin has 9,975,311 shares (4.45%) through controlled entities and 13,636,000 shares (6.08%) as beneficial ownership [120]. - The total number of shares issued by the company as of June 30, 2025, is 224,300,200 shares [126]. - The company has granted a total of 19,181,000 restricted share units to several directors as of June 30, 2025 [126]. - The ownership structure indicates significant control by key executives, with Dr. Yu Rong and Ms. Guo Meiling having substantial stakes in the company [120]. - During the reporting period, the company repurchased a total of 3,834,000 shares at a total cost of HKD 32,897,016 [130]. - The share repurchase was aimed at increasing net asset value per share and earnings per share, authorized at the 2024 annual general meeting [132]. - The company raised approximately HKD 153.4 million from its global offering, with net proceeds allocated as follows: 30% for sales and marketing, 25% for R&D, 20% for testing capabilities and production capacity, 15% for investments and acquisitions, and 10% for working capital [134][135]. - As of June 30, 2025, the actual usage of the net proceeds was HKD 130.4 million, with HKD 23.0 million remaining for investments and acquisitions expected to be utilized by December 31, 2028 [135][136]. Operational Metrics - The company’s high-throughput testing platform can process up to 50,000 samples daily, providing cost-effective gene testing solutions [42]. - The current ratio as of June 30, 2025, was 15.2, significantly higher than 5.4 in 2024 [84]. - The company’s inventory increased to RMB 5,351,000 as of June 30, 2025, compared to RMB 4,609,000 as of December 31, 2024 [143]. - The company’s total assets less current liabilities stood at RMB 649,869,000 as of June 30, 2025, compared to RMB 647,837,000 as of December 31, 2024 [143]. - The group’s trade payables as of June 30, 2025, totaled RMB 25,376,000, slightly down from RMB 25,433,000 as of December 31, 2024 [176]. - The group’s research and development costs for the six months ended June 30, 2025, were RMB 8,151,000, a decrease from RMB 9,934,000 in 2024 [166].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 PACIFIC CENTURY PREMIUM DEVELOPMENTS LIMITED 盈科大衍地產發展有限公司* （於百慕達註冊成立的有限公司） （股份代號：00432） 截至2025年12月31日止年度業績公告 盈科大衍地產發展有限公司（「本公司」）董事會（「董事會」）宣佈本公司及其附屬公司（「本集團」）截至 2025年12月31日止年度之經審核綜合業績。 摘要 – 1 – ‧ 來自持續經營業務的綜合收入增加百分之五十一至港幣10.46億元 ‧ 本公司股東應佔虧損為港幣6,900萬元 ‧ 每股基本虧損：港幣3.38分 ‧ 董事會不建議派發末期股息 業務回顧 物業投資及發展 印尼的物業投資 位於印尼雅加達的頂級商業物業Pacific Century Place, Jakarta（「PCP Jakarta」）的出租率於年內表現保持穩 定，持續為集團的收入來源之一。截至2025年12月31日止年度，已承 ...